Biopheresis Overview

  • Founded
  • 2003

Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Liquidation

Biopheresis General Information

Description

Operator of a bio-medical company intended to develop immunological therapies for the treatment of cancer. The company's bio-medical processes use a medical device, an immuno-affinity column that specifically removes inhibiting sTNFRs from patients' blood, enabling doctors to get technology that removes inhibiting sTNFRs to allow their own TNF-mediated immune response to attack and destroy tumors.

Contact Information

Website
www.oncosorb.de
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Im Neuenheimer Feld 515
  • 69120 Heidelberg
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biopheresis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation 25-Feb-2015 00.000 Completed Bankruptcy: Liquidation
2. Grant 10-Nov-2006 00000 00.000 Completed Startup
1. Early Stage VC (Series A) 12-May-2005 $8.39M $8.39M Completed Startup
To view Biopheresis’s complete valuation and funding history, request access »

Biopheresis Patents

  • 60

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Biopheresis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2005240082-B2 Method and system to remove soluble tnfr1,tnfr2, and il2 in patients Inactive 30-Apr-2004 0000000000
AU-2009227872-A1 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients Active 30-Apr-2004 0000000000
AU-2005240082-A1 Method and system to remove soluble tnfr1,tnfr2, and il2 in patients Active 30-Apr-2004 0000000000
AU-2009227872-B2 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients Inactive 30-Apr-2004 0000000000
CA-2565215-A1 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients Active 30-Apr-2004 A61M1/3472
To view Biopheresis’s complete patent history, request access »

Biopheresis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial